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Glioblastoma is the most aggressive adult primary brain tumor which is incurable despite intensive multimodal treatment. Inter-
and intratumoral heterogeneity poses one of the biggest barriers in the diagnosis and treatment of glioblastoma, causing
diﬀerences in treatment response and outcome. Noninvasive prognostic and predictive tests are highly needed to complement
the current armamentarium. Noninvasive testing of glioblastoma uses multiple techniques that can capture the heterogeneity of
glioblastoma. This set of diagnostic approaches comprises advanced MRI techniques, nuclear imaging, liquid biopsy, and new
integrated approaches including radiogenomics and radiomics. New treatment options such as agents targeted at driver
oncogenes and immunotherapy are currently being developed, but beneﬁt for glioblastoma patients still has to be demonstrated.
Understanding and unraveling tumor heterogeneity and microenvironment can help to create a treatment regime that is
patient-tailored to these speciﬁc tumor characteristics. Improved noninvasive tests are crucial to this success. This review
discusses multiple diagnostic approaches and their eﬀect on predicting and monitoring treatment response in glioblastoma.
1. Introduction
Glioblastoma (GBM) is the most aggressive primary brain
tumor with an incidence of 2-3 cases per 100,000 people
[1]. Currently, a median survival of approximately fourteen
months is achieved with intensive multimodal treatment.
However, despite this intensive treatment, there is no cure
and recurrence of GBM is inevitable [2].
1.1. Diagnosis and Treatment. Diagnostic approaches in
GBM are rapidly evolving. The diagnosis is currently based
on the recently revised WHO criteria (2016) for the
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classiﬁcation of central nervous system tumors. [3]. At pres-
ent, histopathological investigation of a tissue sample from a
suspected GBM lesion is the gold standard for the diagnosis.
This is currently complemented by molecular diagnostics of
which identiﬁcation of O6-methylguanine-DNA-methyl-
transferase (MGMT) methylation, isocitrate dehydrogenase
(IDH) mutation, and 1p19q codeletion is currently the most
valuable in daily clinical practice. Methylation of theMGMT
gene is the only predictive marker for treatment response
available and is predictive of an improved response to
alkylating chemotherapy such as temozolomide [4, 5]. The
IDH mutation status [6] and 1p19q codeletion [7] are of
prognostic value but do not predict treatment response in
patients with GBM. These markers are however of predictive
value in oligodendroglioma [8, 9]. Additional markers such
as telomerase reverse transcriptase promotor (TERT) muta-
tions and alpha-thalassemia syndrome X-linked (ATRX)
can already be used additionally in the classiﬁcation of
GBM subtypes [10, 11].
At the moment, the treatment schedule consists of neuro-
surgery, concurrent chemoradiation therapy, and adjuvant
temozolomide. This provides a median progression-free sur-
vival of almost 7 months [2]. There is no standard treatment
for the recurrent setting. Systemic treatment options include
a temozolomide rechallenge, lomustine, and antiangiogenic
therapy such as bevacizumab. However, eﬀectiveness of these
treatment options is limited. Additionally, reirradiation and
re-resection can be considered depending on the localization
of the tumor and condition of the patient [12].
1.2. Monitoring Treatment Response. Both during and after
treatment for GBM, magnetic resonance imaging (MRI) is
the main modality used in the follow-up and monitoring
of treatment response. Diﬃculties arise in monitoring
response when it comes to the diﬀerentiation between
pseudoprogression, radiation necrosis, and actual tumor pro-
gression. Pseudoprogression is a physiologic posttreatment-
related reaction of brain tissue, based on vascular and cellular
injury from chemoradiation therapy. This leads to inﬂamma-
tion and increased permeability of the blood-brain barrier
(BBB), causing an increase in contrast enhancement on
MRI suggestive of tumor progression but without tumor
recurrence [13, 14]. Radiation necrosis is a direct eﬀect of
radiation therapy, which can mimic tumor progression on
imaging techniques but does not reﬂect actual progression
of the tumor. Timing of MRI changes can help to diﬀerenti-
ate between pseudoprogression, which occurs most com-
monly in the ﬁrst three to six-month posttreatment, and
radiation necrosis which occurs six months to several years
after treatment [15].
Markers are also needed for monitoring treatment
response for patients treated with immunotherapy. On
MRI, these patients may ﬁrst show an increase in size or even
the formation of new (pseudo) lesions due to the antitumor-
mediated immune response and localized inﬂammation,
which does not necessarily deﬁne progressive disease
[16, 17]. At the moment, diﬀerentiating pseudoprogression
from actual tumor progression remains diﬃcult and cur-
rently only follow-up imaging with conventional imaging
methods is available to deﬁne this. Therefore, new imaging
techniques and/or biomarkers to further characterize the
origin of the imaging changes that are observed are needed
to overcome these challenges.
On the other hand, another phenomenon on MRI called
pseudoresponse can also occur, mainly during treatment
with vascular endothelial growth factor (VEGF) signaling
pathway modifying agents such as bevacizumab. Bevacizu-
mab induces a steroid-like eﬀect by normalizing the perme-
ability of the BBB, leading to a rapid decrease in contrast
enhancement. Thus, while the imaging reﬂects reduced
contrast and suggests a posttreatment response, the eﬀects
on overall survival are minimal [13, 18, 19].
1.3. Tumor Heterogeneity. Tumor heterogeneity poses one of
the most important challenges in the current diagnosis and
treatment of GBM, and it is one of the main diﬃculties when
it comes to ﬁnding new treatment options. GBM shows
varying tumor characteristics both between patients and
within individual tumors [20, 21]. Current histological anal-
ysis cannot capture the full spectrum of genotypic and
phenotypic characteristics, especially when only a single
biopsy can be taken.
The intratumoral heterogeneity poses a great challenge in
predicting sensitivity and resistance to systemic therapies. As
one clone within the tumor may be sensitive to one form of
treatment, another clone might harbor certain resistance
mechanisms to this treatment in its speciﬁc tumor microen-
vironment. Intratumoral heterogeneity is a dynamic process
which changes over time and during treatment which poses
challenges in the recurrent setting of GBM, as research has
shown recurrent tumors usually show resistance to the tradi-
tional treatment options and expresses diﬀerent mutations
when compared to the original tumor [20, 22].
Since conventional MRI cannot reﬂect tumor heteroge-
neity, before this can be used as a parameter in daily clin-
ical practice, improved diagnostic approaches should be
developed to identify this heterogeneity.
1.4. Noninvasive Glioblastoma Testing. Noninvasive glioblas-
toma testing (NIGT) combines noninvasive (i.e., nonsurgi-
cal) techniques to represent the tumor as a whole and
provides information on driver mechanisms and tumor
microenvironment, all of which are factors that can/should
be incorporated into the treatment regime. This can be espe-
cially helpful in the selection of patients in order to better
predict response to new therapeutic targets, as the current
options available are limited. Also, the brain is less easily
accessible for taking repeated biopsies, which stresses the
need for noninvasive approaches. New integrated approaches
such as radiogenomics and radiomics can also be an impor-
tant part of NIGT. Radiogenomics is an experimental diag-
nostic and predictive tool which studies the association
between (qualitative) imaging features andmolecularmarkers
[23]. Radiomics on the other hand uses a computational
analysis to extract quantiﬁable information about theunderly-
ing tumor characteristics by high-throughput mining of large
amounts of quantitative features from images based on, for
example, textures, intensities, and shapes [24, 25]. Radiomics
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has already been more extensively studied in, for example,
head-and-neck cancer [26, 27] and lung cancer [28].
The objective of this review is to discuss the already estab-
lished approaches as well as future diagnostics used for mon-
itoring and prediction of treatment response in patients with
GBM by creating a so-called NIGT platform. This includes a
multimodal approach to fully capture the complexity and
heterogeneity of GBM with the use of conventional
techniques such as imaging techniques, enhanced by compu-
tational approaches, and the use of circulating biomarkers.
2. Magnetic Resonance Imaging
MRI is clinically used in diagnosis and follow-up of cerebral
tumors. The use of imaging to predict patient survival has
been applied since as early as 1996 [29, 30]. Features found
to be correlating with a longer survival in GBM are the
presence of nonenhancing tumor and the absence of either
edema, satellites, or multifocality [31]. The Visually Accessi-
ble Rembrandt Images (VASARI) research project aimed to
make MRI features more accurate and reproducible. In this
project, a set of 24 observations describing the morphology
of brain tumors on contrast-enhanced MRI were reported
and analyzed for their prognostic signiﬁcance on overall
survival [32, 33].
2.1. Monitoring Treatment Response. For the evaluation of
tumor response after ﬁrst-line treatment, the Response
Assessment in Neuro-Oncology (RANO) criteria of 2010 is
currently used [34]. A major drawback of these criteria is
its nonvolumetric criteria and lack of use of advanced MR
techniques. For instance, with using only these RANO
criteria, pseudoprogression cannot be distinguished from
radiation necrosis or disease recurrence [35].
Several advanced MR techniques have been developed to
improve standard contrast-enhanced MRI, such as diﬀusion-
weighted imaging (DWI), perfusion imaging, and magnetic
resonance spectroscopy (MRS) [15]. DWI displays the
cellularity within tissue by detecting free diﬀusion of water
molecules. The apparent diﬀusion coeﬃcient (ADC) is a
derived DWI parameter in which the T2 signal from the
original DWI is excluded to overcome the so-called “T2
shine-through eﬀect,” which causes a high signal on DWI
that is not due to restricted diﬀusion. DWI and ADC are
widely used in tumor imaging, where a decrease in ADC
signal has been shown to correlate with increasing tumor
cellularity while an increase in signal correlates with decreas-
ing cellularity as a result of successful treatment [36, 37].
A relatively new DWI technique that has been developed
is functional diﬀusion map (fDM) imaging, which reﬂects
diﬀerences in ADC signal over time. This fDM analysis has
shown to be able to distinguish progressive tumors from sta-
ble and partially responsive tumors [38, 39]. Although this
technique is promising, there is a great variability in proto-
cols collecting and processing DWI/ADC data between dif-
ferent vendors, standing in the way of wide-scale use [40].
Perfusion images can be acquired in various ways, with
dynamic susceptibility-weighted contrast-enhanced MR
(DSC MR) being most widely used. Other perfusion
techniques include dynamic-contrast-enhanced MR (DCE
MR), which is comparable to DSC MR, and arterial spin
labeling (ASL) perfusion, which does not require intravenous
contrast but is more susceptible for artifacts. DSC MR is able
to assess cerebral microvasculature by following an admin-
istered contrast agent as it passed through the microvascu-
lature. Tumors tend to have a higher number and larger
volumes of blood vessels. Furthermore, remodeling of the
extracellular matrix disturbs the BBB and causes leakage
of contrast [14, 41, 42]. By comparing, for example, tumor
areas with healthy brain tissue, relative cerebral blood
volumes (rCBV) can be measured [14, 41]. The presence of
high rCBV has been shown to represent active neovasculari-
zation and viable tumor, whereas normal rCBV in apparent
lesion progression could point to, for example, chemoradia-
tion eﬀects and thereby exclude pseudoprogression and
radionecrosis [43, 44].
MRS can be used to measure the distribution of chemical
metabolites in brain tissue and thereby identifying diﬀer-
ences in metabolic turnover of brain tissue. As high-grade
tumors are highly metabolically active and are accompanied
by a leaky blood-brain barrier, regional diﬀerences can be
found in the spectroscopic proﬁle in tumor depositions,
compared to necrosis, pseudoprogression, and healthy brain
tissue. In 1H-spectroscopy, elevated peaks of lipid, lactate,
choline, and myoinositol and reduced NAA signal are typical
ﬁndings in primary brain tumors [45, 46]. Due to patient and
tumor-speciﬁc diﬀerences, an unequivocal threshold of
metabolic signal ratios cannot be determined making it diﬃ-
cult to establish uniform guidelines and accuracy; however,
MRS changes in time can be of help to strengthen suspicions
on, for example, tumor progression or response [47]. MRS
alone therefore has a moderate diagnostic performance in
diﬀerentiating glioma recurrence from radiation necrosis
and should always be combined with other advanced imag-
ing technologies [48].
2.2. Tumor Heterogeneity and Predicting Treatment
Response. GBM is subdivided into four subcategories based
on histopathological features and speciﬁc mutations and
molecular markers: proneural, neural, mesenchymal, and
classical subtypes. Each subset is associated with speciﬁc
mutations; therefore, identiﬁcation of the subtype by radio-
genomics can provide information on driver mechanisms
in the tumor. Between these subtypes, the proneural subtype
is thought to have the most favorable prognosis [49]. Also,
diﬀerent subtypes react diﬀerently to diﬀerent treatment
options [50]. Radiogenomics can be applied to predict the
GBM subtype. Volumes of both contrast enhancement and
necrosis are higher in tumors with the mesenchymal subtype
compared to the proneural subtype. GBMs with less than 5%
tumor enhancement are mostly of the proneural subtype. On
the other hand, GBMs with less than 5% nonenhanced tumor
rarely represent proneural tumors and are more linked to the
classical or mesenchymal subtype [51, 52].
Radiogenomics can also be used as a tool to predict
mutation status. IDH1-mutation status is associated with a
localization of the tumor in the frontal lobe, a higher percent-
age of noncontrast-enhancing part of the tumor, and the
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presence of cysts on MRI [53, 54]. MRS has recently been
used to predict IDH mutation status. MRS can measure
elevated levels of 2-HG metabolite which is a surrogate
marker for IDH-mutated tumor cells and can correctly
identify IDH mutation status in 88.6% of patients (sensi-
tivity 89.5%, speciﬁcity 81.3%). However, further technical
improvement of this technique, including voxel localiza-
tion, as well as understanding of the impact of tumor
heterogeneity on MRS is needed before it can be used in
daily clinical practice [55, 56].
MGMT-methylated tumors tend to be lateralized to the
left temporal lobe whereas MGMT-unmethylated tumors
are more frequent in the right hemisphere. This may be due
to asymmetry in brain structure, function, and gene expres-
sion between the hemispheres [57]. MGMT-unmethylated
tumors have a higher percentage of tumor enhancement
and T2/FLAIR hyperintensity when compared to MGMT-
methylated tumors [53]. Several imaging features are poten-
tial indicative of MGMT methylation such as mixed nodular
enhancement, limited edema, and moderately increased
rCBV [23].
The presence of the 1p19q codeletion is linked to classical
oligodendroglial MRI characteristics such as heterogeneous
T2 signal intensity and the presence of calciﬁcations.
Advanced imaging techniques have not yet shown to
improve the capacity to identify the 1p19q codeletion over
conventional MRI to identify oligodendroglial tumors [23].
Epidermal growth factor receptor (EGFR) ampliﬁcation
is associated with a signiﬁcant higher percentage of contrast
enhancement and T2/FLAIR hyperintensity compared with
tumors lacking EGFR ampliﬁcation. Also, EGFR ampliﬁca-
tion and EGFRvIII mutant GBMs are commonly associated
with localization in the left temporal lobe [53].
Apart from already mentioned molecular markers, other
known driver genes, such as phosphatase and tensin homolog
(PTEN), platelet-derived growth factor receptorA (PDGFRA),
cyclin-dependent kinase inhibitor 2A (CDKN2A), retinoblas-
toma 1 (RB1), and tumor protein 53 (TP53) are also under
investigationandsigniﬁcant imagecorrelations for these genes
have already been identiﬁed [58].
The aforementioned advanced imaging techniques can
also aid in exploring tumor heterogeneity. Both CBV and
ADC measurements are found to be inﬂuenced by tumor
aggressiveness, and it is suggested that the heterogeneous
genetic and cellular expression patterns within GBM inﬂu-
ence anatomic and physiologic MR imaging [59]. These
techniques can also guide neurosurgeons in determining
the biopsy location.
MRI-based radiomics for GBM is a relatively new area for
which little research has been published to this date. A study
of 82 GBM patients reported favorable results in the perfor-
mance of texture features in predicting the molecular subtype
and 12-month survival [60]. For the prediction of 12-month
survival based on pattern analysis, sensitivity and speciﬁcity
of 0.86 and 0.64, respectively, are reported. The prediction
of GBM subtype was also investigated. Accuracy for classical,
mesenchymal, neural, and proneural subtypes was 0.88, 0.70,
0.85, and 0.93, respectively [61]. Another study used
machine-learning techniques and found an accuracy of
almost 80% in predicting overall survival and an accuracy
of 76% in predicting the molecular subtype [62].
MRI texture analysis has been found to be able to facili-
tate in characterizing intratumoral heterogeneity and may
therefore aid in identifying genetically diﬀerent components
of the tumor and understanding its consequences for
prognosis, treatment sensitivity, and resistance [58]. It has
been shown that radiomics features are able to visualize
spatial gene expression within a tumor [63]. Patients can be
subdivided into diﬀerent clusters using texture features. For
example, one study divided patients into the “premultifocal,”
“spherical,” or “rim-enhancing” cluster based on quantitative
imaging features. Each of these clusters was linked to diﬀer-
ent signaling pathways and microarrays and has been shown
to be prognostic for survival [64].
Radiomics was found to have prognostic value for both
survival and progression in patients with recurrent GBM
receiving bevacizumab. Therefore, it might be possible to
develop pretreatment biomarkers based on radiomics to
predict beneﬁt from bevacizumab [65, 66]. These ﬁndings
illustrate the possibilities of applying radiomics in the predic-
tion of treatment response in patients with GBM. Further
optimization of this technique and validation of radiomics
proﬁles as predictors for diﬀerent mutation statuses and/or
survival are needed before it can be used in clinical practice.
3. Nuclear Imaging
Molecular imaging by the use of positron emission tomogra-
phy (PET) is increasingly being implemented into clinical
practice for treatment planning and response monitoring of
GBM. The most common is ﬂuorodeoxyglucose (18F-FDG)
PET imaging; however, compared to other organ systems,
18F-FDG-PET imaging of brain tumors presents unique chal-
lenges because of the high background glucose metabolism of
normal gray matter masking detection of malignant lesions.
Thus, the use of 18F-FDG-PET in brain tumors albeit is lim-
ited, although in high-grade glioma, 18F-FDG-PET imaging
can be used to identify metabolically active disease which
correlates with tumor grade [67, 68]. Because of the limited
utility of 18F-FDG-PET, the RANO working group has rec-
ommended the use of radio-labeled amino acid tracers for
PET (AA-PET) instead [69].
Amino acid tracers such as O-(2-[18F]-ﬂuoroethyl)-L-
tyrosine (18F-FET) and L-[methyl-11C]methionine (11C-
MET) are currently applied in clinical practice in GBM. Both
18F-FET and 11C-MET show rapid uptake into tumors and
can be visualized with high contrast [70]. 11C has a short
half-life time of 20 minutes, making it less useful for clinical
practice. 18F has a much longer half-life time (120 minutes)
and is only taken up by cells through speciﬁc L-
transporters—LAT2—that are highly and predominantly
expressed on glioma tumor cells. This ensures a high and
selective uptake of the tracer in tumor tissue, with a low to
negligible background signal in normal brain tissue or in
surrounding inﬂammatory areas. Thus, 18F-FET-PET has a
high sensitivity and speciﬁcity for the detection of malignant
gliomas [71–74]. A biopsy-controlled study has shown that
with a combination of MRI and 18F-FET-PET, a sensitivity
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of 93% and a speciﬁcity of 94% can be achieved [71]. Other
amino acid tracers currently under investigation include 18F-
FDOPA (phenyl alanine) PET, a dopaminergic tracer, and
alpha11C-L-methyl-tryptophan PET, a tryptophan analog.
3.1. Monitoring Treatment Response. 18F-FET-PET currently
has multiple potential clinical applications including the
monitoring of treatment response and can distinguish tumor
recurrence from radiation necrosis or pseudoprogression
[69]. A study investigating 18F-FET for PET-guided radio-
therapy concluded that size and geometrical location of gross
tumor volume and biological tumor volume, deﬁned by 18F-
FET uptake, were signiﬁcantly diﬀerent in patients where the
biological tumor volume extended up to 10–20mm from the
margin of contrast enhancement on MRI, potentially
improving local tumor control due to improved radiotherapy
planning using 18F-FET-PET [75]. Multiple studies have
shown that both 18F-FET-PET and 18F-FDOPA-PET have a
higher diagnostic accuracy than conventional MRI in
diﬀerentiating glioma recurrence from posttreatment tissue
changes. For example, studies show a sensitivity and speciﬁc-
ity of 92.3% and 44.4%, respectively, for MRI compared to
100% and 88.89% for 18F-FDOPA-PET [76–79]. A prospec-
tive study investigating the predictive value of 18F-FET-PET
in patients treated with chemoradiation has shown that a
decrease of 18F-FET-PET accumulation reﬂects tumor
response to the therapeutic intervention at an early stage of
the disease and predicts outcome, whereas contrast-
enhanced MRI did not [78].
3.2. Tumor Heterogeneity and Predicting Treatment Response.
Correlation between diﬀerent types of AA-PET standard
uptake values (SUV) and molecular markers, in the context
of radiogenomics, is currently under investigation. A longitu-
dinal prospective study has investigated 18F-FET-PET as an
imaging biomarker, and they concluded that the biological
tumor volume before treatment was a strong prognostic
marker for both overall- and progression-free survival
independent of treatment as well asMGMT promotermethyl-
ation and other patient- and tumor-related factors. Moreover,
tumor uptake kinetics before and after treatment (i.e., TAC
curves) is correlated with progression-free survival [80].
A recent study demonstrated the relationship between
11C-MET-PET and IDH1 mutation and found that SUVmax
and SUVratio were inversely correlated with IDH1 mutation
[81]. Moreover, a study which combined MRI and alpha[C-
11]-L-methyl-tryptophan PET imaging showed prognostic
imaging factors such as T1-contrast/PET volume ratios and
metabolic volume, which are associated with EGFR ampliﬁ-
cation and MGMT methylation status [82]. To assess the
potential of radiogenomics as a diagnostic and predictive
tool, well-deﬁned preclinical models with speciﬁc driver
mutations are needed that can be used to validate the sensi-
tivity and speciﬁcity of radiogenomics. The ability to identify
prognostic or molecular response markers based on imaging
features derived from routine diagnostic procedures (MRI,
PET, and computed tomography (CT)) provides an attractive
way of predicting treatment response in GBM.
Tumor hypoxia is a common feature of the tumor micro-
environment in GBM and contributes to increased malig-
nancy, poor prognosis, and resistance to radiotherapy and
alkylating chemotherapy such a temozolomide [83–85].
Acute and chronic hypoxic areas ﬂuctuate in human tumors
and contribute to spatial and temporal intratumoral hetero-
geneity [86, 87]. This has a signiﬁcant impact on resistance
to conventional treatment. Therefore, GBM patients might
beneﬁt from hypoxia-targeting drugs [21]. Molecular imag-
ing of tumor hypoxia could aid in the selection of patients
with hypoxic tumors, which could beneﬁt from speciﬁc
antihypoxic therapies. The eﬃcacy of antihypoxic treatments
will depend on the presence of hypoxia. Several 2-nitroimi-
dazoles, labeled with 18F, have already been investigated in
patients to identify hypoxia [88]. In extensive preclinical
models and clinical trials, 18F-HX4-PET has shown to be
a promising and nontoxic probe for hypoxia [89–91].
Repeated hypoxia imaging during the course of disease
and treatment will demonstrate the extent of spatial and
temporal ﬂuctuations in tumor hypoxia and is likely impor-
tant in scheduling hypoxia-modifying drug in combination
with conventional treatments.
4. Liquid Biopsy
Liquid biopsy (LB) has entered clinical practice in the treat-
ment of several cancer types, including breast and colorectal
cancer [92, 93]. LB studies circulating biomarkers which refer
to measurable biological molecules found in blood, urine,
and or other body ﬂuids, like cerebrospinal ﬂuid (CSF).
Although LB has reﬁned the individual treatment for several
cancer subtypes, relatively little progress has been made with
regard to validation of circulating biomarkers for primary
brain tumors. Nevertheless, although the translation of bio-
marker development into neuro-oncology is lagging behind
compared to general oncology, the prerequisites for adequate
extrapolation are present, mostly in experimental studies
[94]. In these studies, circulating tumor cells (CTCs), circu-
lating free nuclear acids (cfNA), extracellular vesicles, and
circulating proteins and metabolites have been described.
For brain tumors, where noninvasive procedures are
complex, precarious, and may be nonrepresentative for
outcome, circulating biomarkers pose a realistic option.
For the inoperable patients, which mostly occurs in the
recurrent setting, circulating biomarkers could be the source
of a molecular proﬁle of the relapsed tumor, allowing clini-
cians to identify potentially druggable molecular alterations
driving recurrence.
4.1. Monitoring Treatment Response. miRNAs are small
(about 21–24 nucleotides) noncoding regulatory RNA mole-
cules and can be detected as cell-free entities or as the content
of circulating extracellular vesicles (EVs) in plasma/serum or
CSF. EVs are small nanometer size membrane-enclosed
particles that are released from GBM living tumor cells.
EVs that can be isolated from both blood and CSF are a rich
source of tumor-derived molecules such as DNA, miRNA,
mRNA, proteins, lipids, and metabolites, because the struc-
ture of EVs protects them from nucleases and proteases [95].
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The human genome encodes for miRNAs which have
been shown to regulate most hallmarks of tumor develop-
ment and progression via transcriptional silencing or transla-
tion inhibition of both oncogene and suppressor genes and
have tumor/tissue-speciﬁc signatures [96]. miRNAs have
been described in GBM, mostly from resected specimens.
miR-21 is the most reliable plasma biomarker in glioma
diagnosis and seems to be valuable distinguishing tumor
progression from pseudoprogression or radionecrosis [97].
Exosomal miRNA-21 in CSF of glioma patients has been
shown to correlate with glioma recurrence [98]. An increase
in levels of blood-born annexin V-positive microvesicles dur-
ing chemoradiation is associated with earlier recurrence and
shorter overall survival. Since the number of patients
included in this analysis was only small (n = 16), further
investigation is needed [99].
4.2. Tumor Heterogeneity and Predicting Treatment
Response. The ability to detect CTCs in GBM patients has
been established [100]. Also, using single-cell genome
sequencing, some unique mutations were found in the CTCs
as well as in the parental tumor [101]. However, the most
important limiting factor for the clinical implementation of
CTCs is their scarcity, which makes it diﬃcult to adequately
assess GBM heterogeneity. Also, it has not yet been estab-
lished in GBM if CTCs can be identiﬁed which show charac-
teristics of brain tumor-initiating cells.
Circulating tumor DNA (ctDNA) is much more abun-
dant than CTCs and contains the mutations present in
tumors [102]. In GBM patients, a lower rate of ctDNA is
detected compared to other solid tumors, mainly due to the
only partially disrupted BBB. In several small retrospective
studies, ctDNAs were successfully detected in GBM patients
and multiple molecular alterations were characterized
including loss of heterozygosity (LOH) in chromosome arms
1p, 19q and 10q, IDH1, and EGFRvIII mutations as well as
methylation of promoters of MGMT, PTEN, and CDKN2A
[103–105]. Only few studies have reported the plasma half-
life of ctDNA. The available data propose that the fast turn-
over of ctDNA reﬂects tumor homeostasis [106]. Until
now, the clinical utility of candidate ctDNAs as biomarkers
for patients with GBM has not been demonstrated and
large-scale prospective studies are needed before their imple-
mentation in clinical practice.
miR-130a was found to positively correlate with temozo-
lomide response in GBM patients, independent fromMGMT
methylation status [107]. miR-603 is another regulator of
MGMT and could complement assessment of MGMT
methylation, which alone cannot completely explain temozo-
lomide eﬃciency, as a predictive marker for treatment
response [108]. miR-181d levels in the serum of GBM
patients are also shown to correlate with response to temozo-
lomide, since this miRNA, like miR-603, is directly involved
in the downregulation of MGMT [109].
Mutant IDH enzymes acquire neomorphic enzymatic
activity, thereby catalyzing the production of D-2-
hydroxyglutarate (D2HG), an oncometabolite that accumu-
lates at high levels and inhibits several enzymes notably
involved in histones and DNA demethylation [110]. In most
patients with IDH1/2 mutant gliomas, plasma D2HG values
are in the normal range [111], suggesting limited clinical value
of this oncometabolite. However, combining this technique
with MRS which can, as mentioned before, measure D2HG
metabolite concentrations in brain tissue, might be useful in
exploring IDHmutation status.
Several circulating proteins have been evaluated and
include proteins with cell lineage such asGFAP [112],NCAM
[113], and S100B [114], matricellular proteins and matrix
metalloproteinases such as YKL-40, MMP2, MMP9 [115],
TIMP-1, and osteopontin [116], and cytokines [117], growth
factors, and growth factor receptors such as VEGF, FGF-2,
PlGF, IGFBP-5, EGFR, VEGFR1 [118], and TGF-β1 [119].
Further validation of these biomarkers is warranted.
5. Discussion and Future Perspectives
Advanced MR imaging techniques, nuclear imaging, liquid
biopsy and integrated radiogenomics, and radiomics
approaches are examples of noninvasive diagnostic methods
to uncover underlying tumor characteristics. GBM is a
challenging tumor both from a diagnostic and therapeutic
point of view. Recent advances are made when it comes to
molecular markers and the understanding of underlying
driver oncogenes and tumor microenvironment, all factors
which contribute to treatment sensitivity and resistance.
Diagnostic methods to accurately identify these factors and
their impact on outcome are needed to be able to put this
knowledge to clinical use.
Tumor heterogeneity poses a big challenge in the use of
targeted treatment approaches. Apart from heterogeneity
on the genetic level, nongenetic factors such as the tumor
microenvironment also inﬂuence the development on cancer
cell populations [120]. Diﬀerent niches have been identiﬁed
in GBM harboring very diﬀerent epigenetic and environmen-
tal factors which also play a role in treatment resistance and
heterogeneity [121]. These diﬀerences make it challenging
to create one uniform treatment schedule for GBM, and a
comprehensive insight into the behavior of these distinct
tumor cell populations is needed.
The diagnostic modalities previously discussed all have
future possibilities to improve the understanding of tumor
heterogeneity and the prediction of treatment response as
well as the monitoring of treatment response with regard to
the diﬀerentiation of pseudoprogression, radiation necrosis,
and actual tumor progression. The latter is especially impor-
tant when it comes to patients treated with immunotherapy,
for which no adequate distinction between pseudoprogres-
sion and actual progression can currently be made.
MRI is already well established within the clinic of GBM;
further optimization through higher resolutions (e.g., ultra-
high ﬁeld MRI), wider use of advanced imaging techniques,
and further research, including clinical validation, on the
application of radiogenomics will improve the diagnostic
power ofMRI. The same applies to nuclear imaging, especially
diﬀerent types of AA-PET for which additional studies on
known amino acid tracers and the development of new tracers
to improve diagnostic accuracy, both in the setting of the pri-
mary diagnosis as well as in the monitoring of treatment
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response and patient follow-up, are warranted. Radiomics is
an important topic in diﬀerent types of solid tumors and still
relatively new in GBM. Radiomics analysis is one of the most
promising techniques for the diﬀerentiation between diﬀerent
GBM subsets and in evaluating and monitoring intratumoral
heterogeneity [122]. Ideally predictive radiomics models are
created as predictors for GBM subtypes as has already been
established using radiomics in other types of solid tumors
[24]. Before radiomics can be applied, prospective validation
is needed as well as standardization of imaging protocols,
imaging segmentation, and feature extraction to ensure inter-
operability of multicenter radiomics studies [123].
Liquid biopsy provides a diﬀerent approach for under-
standing tumor characteristics. Further research should focus
on determining the clinical value of liquid biopsy and also
which liquid source and which biomarker technique to use.
Also, the possibility to use liquid biopsy in patients after a
tumor resection as a marker for tumor recurrence has yet
to be studied. Tumor heterogeneity will remain an important
pitfall in liquid biopsy technique; this might be overcome by
combining liquid biopsy with other noninvasive markers but
will remain a challenge.
Future research should focus on determining the
sensitivity and speciﬁcity and validating the techniques
previously discussed for GBM. Being able to understand
and unravel intratumoral heterogeneity provides clinicians
with important information to create the most optimal
treatment regime, and this should therefore be the focus
of future studies.
NIGT oﬀers a noninvasive panel to understand the
driver mechanisms as potential treatment targets as well
as identifying the tumor microenvironment. Combining
diﬀerent diagnostic modalities aims to achieve optimal
diagnostic power for identiﬁcation of tumor characteristics.
Understanding the tumor microenvironment (e.g., hypoxia,
angiogenesis, and immune inﬁltration) can help in ﬁnding
new ways to treat GBM or to alter the tumor microenviron-
ment to improve the eﬀectiveness of systemic therapies and
radiotherapy. Unique to the brain microenvironment is the
BBB which limits eﬀectiveness of therapeutic agents.
Advances in imaging allow the visualization of changes in
the tumor microenvironment and tissue architecture as a
response to treatment and can therefore serve as a marker
for treatment response.
Given the limitations of each of the currently available
noninvasive tools, these diagnostic methods are ideally com-
bined into a so-called NIGT platform: a multimodal nonin-
vasive approach to visualize the tumor and its underlying
tumor characteristics in a spatially and temporally relevant
manner. Using this NIGT platform, predictive models for
GBM can be created, both in the primary and the recurrent
setting. This will guide clinicians in selecting the appropriate
treatment option, treatment monitoring, and adaptation in
the era of patient-tailored precision medicine.
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